Are you sure you want to hide the widget forever? If you need it back, please clear your cookies.
Content
Colors
Color Filters
Navigation
Selected Language
English (United States)
All Languages
Accessibility Statement
Our Commitment to Accessibility
We are committed to ensuring digital accessibility for people with disabilities. We are continually improving the user experience for everyone, and applying the relevant accessibility standards to help users with various disabilities access our website effectively.
Compliance Status
Our website strives to conform to the Web Content Accessibility Guidelines (WCAG) 2.1 Level AA standards. We also aim to be compliant with the Americans with Disabilities Act (ADA) and the European Accessibility Act requirements. These guidelines and regulations explain how to make web content more accessible to people with a wide range of disabilities. We acknowledge that some aspects of our website may not yet achieve full compliance, and we are actively working to address these areas.
Accessibility Features Available
Our website implements the Accessibly App, which provides a variety of tools to enhance website accessibility:
Visual Adjustments
Bigger Text: Increase text size up to 3x for better readability (WCAG 2.1/1.4.4)
Bigger Cursor: Enhanced cursor visibility for easier navigation
Color Adjustments: Invert colors, adjust contrast, brightness, and saturation
Grayscale Mode: Convert website to grayscale for users with visual impairments
Hide Images: Reduce visual distractions for easier reading
Reading and Navigation Aids
Reading Line: Adds a guide line to help follow text
Reading Mask: Places a mask over text to isolate lines and enhance focus
Readable Fonts: Converts to highly legible fonts for better comprehension
Highlight Links: Makes links more prominent for easier navigation
Dyslexic Fonts: Special typography for users with dyslexia
Page Structure: Simplified layout options for easier navigation
Assistive Technologies
Keyboard Navigation: Full website control using keyboard (Tab, Shift+Tab, Enter)
Alt Text for Images: AI-generated image descriptions where manual ones aren't provided
Read Page Aloud: Text-to-speech functionality
Stop Animations: Pause motion content for users with vestibular disorders
Limitations and Feedback
Despite our best efforts to ensure accessibility, there may be some limitations. Content provided by third parties, user-generated content, or certain legacy pages may not be fully accessible. We are continuously working to improve our website's accessibility.
We welcome your feedback on the accessibility of our website. If you encounter any barriers or have suggestions for improvement, please contact us. We are committed to addressing these issues promptly.
Technical Information
The accessibility features on this website are provided through the Accessibly App, which utilizes several technologies including HTML, CSS, JavaScript, and various frameworks to enhance accessibility. Our implementation strives to be compatible with major screen readers and assistive technologies.
Legal Disclaimer
While we strive to adhere to WCAG 2.1 Level AA standards and provide accessible content, we cannot guarantee that our website will be accessible to all users under all circumstances. This website is provided 'as is' without any representations or warranties, express or implied.
In no event shall we be liable for any damages arising from or related to:
Inability to access or use the website
Any alleged non-compliance with accessibility laws or regulations
Any disruption or errors in the functionality of accessibility features
By using this website, you agree to hold us harmless from any claims related to website accessibility issues. We are committed to addressing accessibility barriers in good faith but cannot guarantee immediate resolution in all cases.
Contact Us
If you have any questions about our accessibility efforts or encounter any barriers while using our website, please contact us.
Your medical cannabis journey simplified: find partnered dispensaries, explore pricing options, earn rewards, and get answers to FAQs, all in one spot.
In May 2024, the United States Department of Justice released a new proposal to reclassify marijuana into a category of less dangerous, prescription-eligible drugs. The movement plans to officially initiate the process of changing the regulatory status of cannabis products recognized as marijuana — downgrading the substance from the highly restricted and illegal Schedule I classification to Schedule III.
Because the categorization of a controlled substance determines its availability, accessibility, and legal consequences, marijuana’s transition to Schedule III status would entail easier access to the drug by medical patients and clinical researchers across the country. Reclassifying marijuana into the Schedule III category will put medical cannabis in the class of drugs that have accepted medical use in the United States, with lower potential for abuse and addiction than legal prescription drugs listed as Schedule II, such as hydrocodone (Vicodin) or methylphenidate (Ritalin).
Drugs in Schedule III are only available by prescription for the treatment of certain health conditions, and the class includes substances like ketamine, synthetic steroids, or Tylenol with codeine. So, rather than existing under complete federal prohibition, cannabis-derived drugs could be available by prescription, and those with a prescription would not face federal charges for possession of the drug.
What does this mean for the purveyors of medical cannabis products? More specifically, how will the new legal status of medical cannabis change producers’ ability to market their products containing legal marijuana? This article will explore these questions and clarify the restrictions on cannabis advertising in the United States, both current and in the potential future.
Current Rules for Marketing Cannabis Products
Since the enactment of the Controlled Substances Act (CSA) by the Nixon administration in 1970, marijuana (the legal term for cannabis plants, parts, and derivatives with over 0.3% tetrahydrocannabinol (THC)) has been classified as a Schedule I substance. This class of controlled substances is considered highly addictive and unsafe, and they are seen as having no accepted medical uses. Moreover, the possession of any of these drugs is a felony according to the US federal government, although individual states that have legalized cannabis recognize differing laws surrounding marijuana possession.
Hence, with cannabis’ status as a Schedule I drug under the CSA, advertising for cannabis products classified as marijuana transmitted by interstate commerce is generally prohibited. Furthermore, since cannabis is federally illegal, using federal funds or federal services to advertise products could result in criminal penalties. This means marketing cannabis products via cross-state radio or television programs, and interstate telemarketing using federal airwaves is technically illegal. It is also illegal to transmit cannabis advertisements through mail using the US postal system.
Currently, online advertisements for cannabis businesses are in a legal gray area. However, cannabis advertising on many platforms is prohibited, depending on the service provider. Whether cannabis businesses may market to the users of various social media sites or apps depends on factors such as a particular platform’s terms and conditions, the type of product being advertised, or the local laws of the company’s location.
Most states with legalized medicinal or recreational cannabis systems have already enacted their own regulations concerning advertisements for cannabis that reach the general public. These rules vary by state, with the range of possible restrictions including the size or visibility of physical signs, proximity of advertisements to schools, various advertisement content restrictions, and eligibility for event sponsorship. In addition, there are other regulations surrounding cannabis advertising that have been enacted at local or municipal levels.
Advertisements for products containing cannabidiol (CBD) are also subject to state-level and local restrictions. Despite having been removed from the CSA after the enactment of the 2018 US Farm Bill, CBD products derived from hemp plants (a variety of cannabis plants containing less than 0.3% THC) are still subject to the rules of individual states. Furthermore, there are other FDA-enforced sanctions on how CBD products may be advertised.
How Will the Reclassification of Cannabis Affect Marketing Restrictions?
Regulations for medical cannabis ads will still be subject to state and local level restrictions just as they are today. The movement to shift marijuana from Schedule I to Schedule III will not result in the national legalization of state-specific medical cannabis programs. Medical cannabis businesses, which may operate legally within the rules of their locations, will still generally be barred from marketing their products to consumers at the national level. This is in large part because, although cannabis products will no longer be classified as strictly illegal substances by the federal government, cannabis will still be a controlled substance available only by prescription.
See If You Qualify For Medical Marijuana -Select Your State!
Prescription drug advertisements are overseen by the US Food and Drug Administration (FDA), and medicines that have not been approved by the FDA cannot be legally sold or promoted to the general public. Currently, the only cannabis-derived prescription drug that has been approved for medical use by the association is the CBD-based prescription medication Epidiolex, which is used to treat severe seizure disorders.
Therefore, since cannabis will only be legal to get by prescription, only FDA-approved prescription drugs will be technically legal to market to buyers at the national level. Yet, even FDA-approved cannabis-derived drug advertisements can still be required to meet the demands of state-specific laws about advertisements for cannabis products.
Thus, shifting cannabis to the Schedule III substance class could mean that more states and localities will move to enact their own laws about how and where cannabis-derived prescription drugs may be advertised to the public.
On the other hand, the rescheduling of marijuana to Schedule III opens the possibility for new developments in drug trials by making it easier for researchers to access cannabis-derived substances, so other cannabis-derived medicines may enter the market and be eligible for advertising to the public.
Also, the new classification of cannabis will make it possible for the FDA to approve other cannabis-containing drugs that were strictly illegal and unavailable in the US before. For example, the FDA could move to approve the THC/CBD-based medication called Sativex, which is used to treat symptoms associated with multiple sclerosis and was approved in the UK over a decade ago, as well as in over 25 countries since then.
Only approved prescription medicines like these would be able to legally make promotional material for different types of marketing in various states. So, you won’t be seeing products like the bud you find at a dispensary in drug advertisements any time soon. Instead, advertising would typically be limited to controlled pharmaceutical products approved by federal agencies for the treatment of specific diseases.
Cannabis Advertising Online
Currently, social media platforms such as Facebook, Discord, Instagram, Snapchat, and TikTok have varying degrees of prohibition for cannabis advertising. The inconsistency makes the rules both hard to follow and enforce on these platforms. Some platforms will allow paid advertisements for cannabis in states where it is legal, while others fully ban paid advertising for cannabis products.
There is more flexibility, however, when it comes to allowing advertisements marketing hemp-derived products, such as CBD oil. But the inconsistency in rule-making also emerges in this area because not all social media platforms distinguish CBD-based cannabis products from other cannabis products, which essentially excludes CBD products.
Similarly, platforms like Google may provide search engine optimization (SEO) services for cannabis products, while also maintaining restrictions on direct advertising. For example, these providers may limit the visibility of certain ads or adjust SEO strategies to stop underage people from viewing them.
Reducing Cannabis Stigma Could Bring Unexpected Changes
Overall, moving marijuana products from the list of Schedule I substances will be a remarkable change for US drug policy and the culture surrounding cannabis. Yet, the details of advertising freedom for cannabis businesses are unlikely to drastically change, as most statewide legal cannabis programs will still have to operate outside federal law and regulations, and independent online media platforms maintain the right to establish terms and conditions about cannabis ads on their sites.
Nevertheless, perhaps the change in scheduling will bring about cultural effects that will change advertising through shifting attitudes about cannabis use. For example, changes in the public’s acceptance of cannabis may encourage more individual social media providers to be open to expanding their terms to include cannabis ads for legal states. This would mean that more medical, and even recreational, cannabis businesses would be able to use platforms, such as Reddit and TikTok, to market their products to potential consumers of legal age in cannabis-friendly regions.
Sheldon Sommer is a Southern Californian philosopher with a lifelong interest in the biological world. She is enthusiastic to contribute her fascination with philosophy, natural history, psychology, botany, biochemistry and other related topics to providing cannabis education for the similarly curious. Outside of writing, she enjoys painting, singing opera and Taylor Swift songs, as well as spending quality time with a certain beloved orange kitty cat.
What Is Decarboxylation? In scientific terms, decarboxylation is a chemical reaction that removes a carboxyl group from a molecule. A carboxyl group in molecular form is identified as COOH, or a carbon atom that is double-bonded to an oxygen and an -OH group. Decarboxylation occurs naturally at a very slow rate, but it can be…
Migraines are far more debilitating than typical headaches, often disrupting daily life. More and more people are turning to cannabis to manage their chronic pain, with migraines being the top reason among headache patients. Cannabis is such a powerful tool for migraine and pain relief that many patients even use medical marijuana in place of…
Let’s have a real conversation. Every year, when the Fourth of July rolls around, I see the fireworks and flags and hear all the loud talk about freedom. And every year, I find myself sitting here asking the same damn question: Whose freedom are we really celebrating? Because it sure as hell doesn’t feel like…
Jared Shaw, a former Oklahoma State University basketball player, has been arrested for cannabis possession in Indonesia. The country’s strict anti-drug laws mean he could be facing the death penalty. Shaw is from Dallas, Texas. He attended Dallas ISD’s Carter High School, where he was District 11- 4A’s Defensive Player of the Year in his…
Even though cannabis is more accessible than ever, there are still many places where it’s difficult or impossible to access. Artificial, semi- or fully synthetic cannabinoid products meant to mimic the effects of cannabis tend to proliferate in these areas. Unfortunately, most of these fake chemical products are unregulated and unsafe, with side effects that…
The statements made regarding cannabis products on this website have not been evaluated by the Food and Drug Administration (FDA). Cannabis is not an FDA-approved substance and is still illegal under federal law. The information provided on this website is intended for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It is not intended as medical advice and should not be considered as a substitute for advice from a healthcare professional. We strongly recommend that you consult with a physician or other qualified healthcare provider before using any cannabis products. The use of any information provided on this website is solely at your own risk.